Recursion Pharmaceuticals
RXRXClinical-stage biotech that uses AI and automated lab work to discover medicines. Its platform trains models on images of cells in a lab-in-the-loop cycle of experiments and machine learning, and its pipeline covers oncology and rare diseases such as FAP.
Product
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Recursion OS Platform
Drug-discovery platform combining automated cell-biology experiments with machine-learning models over the resulting data.
Closest alternatives 5
Similar products 11
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Total funding
-
Pre-IPO financing reporting: $448.9M equity raised plus a $30M Bayer collaboration upfront payment (2021-04, ahead of Recursion's IPO). Corrects the previously recorded $600M.
- Market cap
-
Third-party database · 27 Aug 2026 aggregator
Refreshed against the listing's own page.
- Founded
-
Regulatory filing · 11 Sep 2026
FY2023 10-K: "Recursion was founded in 2013."
- Revenue (TTM)
-
Regulatory filing · 30 Jun 2026
Trailing twelve months to 2026-06-30, added from two filings: FY2025 total revenue $74,681K (10-K) - six months to 2025-06-30 $33,968K + six months to 2026-06-30 $14,143K (10-Q filed 2026-08-05: "Total revenue 7,670 19,223 14,143 33,968") = $54,856K. Neither filing states the TTM figure itself.
- Description
-
Regulatory filing · 25 Feb 2026
FY2025 10-K: "We have built an end-to-end, AI-native platform that spans biological discovery, small molecule design, and clinical development".
Open Recursion Pharmaceuticals in the directory
Something wrong here? Send a correction — quote this company id: recursion-pharmaceuticals.